Severe asthma is associated with T helper (TH) 2 and 17 cell activation, airway neutrophilia and phosphoinositide-3-kinase (PI3K) activation. Asthma exacerbations are commonly caused by rhinovirus (RV) and also associated with PI3K-driven inflammation. Anthraquinone derivatives have been shown to reduce PI3K-mediated AKT phosphorylation in-vitro.
BALB/c mice were sensitized and challenged with crude house dust mite extract to induce allergic airways disease and treated with mitoxantrone and a novel non-cytotoxic anthraquinone derivative. Allergic mice were also infected with RV1B to induce an exacerbation.
Anthraquinone treatment reduced AKT phosphorylation, hypoxia-inducible factor-1α and vascular endothelial growth factor expression, and ameliorated allergen- and RV-induced airways hyprereactivity, neutrophilic and eosinophilic inflammation, cytokine/chemokine expression, mucus hypersecretion, and expression of TH2 proteins in the airways. Anthraquinones also boosted type 1 interferon responses and limited RV replication in the lung.
Citation: Cesar de Souza Alves C, Collison A, Hatchwell L, Plank M, Morten M, Foster PS, et al. (2013) Inhibiting AKT Phosphorylation Employing Non-Cytotoxic Anthraquinones Ameliorates TH2 Mediated Allergic Airways Disease and Rhinovirus Exacerbation . PLoS ONE8(11): e79565. https://doi.org/10.1371/journal.pone.0079565
Editor: Junji Yodoi, Institute for Virus Research, Laboratory of Infection and Prevention, Japan
Received: June 18, 2012; Accepted: October 2, 2013; Published: November 5, 2013
Copyright: © 2013 Cesar de Souza Alves et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the National Health Medical Research Council (NH&MRC) (J.M., P.F.), the Hunter Medical Research Institute (J.M., P.F.), the Hunter Children's Research Foundation (J.M., P.F.) and an NH&MRC Health Professional Research Fellowship (J.M.). C.C.S.A., C.F.C., H.C.T., M.V.A. and A.P.F. were supported by CAPES, CNPq and FAPEMIG grants. S.L.J. was supported by a Chair from Asthma UK (CH1155). This work was supported in part by MRC Centre grant G1000758 and ERC FP7 Advanced Grant 233015 (to S.L.J). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: The authors have declared that no competing interests exist.
It is estimated that asthma affects more than 300 million people worldwide . Asthma is characterized by airways hyperreactivity (AHR) and inflammation, mucus hypersecretion, and an aberrant T cell response . Accumulation of eosinophils, neutrophils and lymphocytes in the airways correlate with disease severity and anti-inflammatory treatments ameliorate episodic airways obstruction, which is the clinical hallmark of asthma [3,4]. Airways inflammation is tightly regulated and involves the release of interleukin (IL)-13 and IL-5 produced by T helper type 2 (TH2) cells and natural killer T cells, IL-17 by TH17 cells, as well as chemokines by residential lung and innate immune cells [5–7]. IL-13 also induces mucus production in a signal transducer and activator of transcription 6 (STAT6)-dependent manner and is both sufficient and required for the development of AHR and goblet cell hyperplasia [8–10]. Acute asthma exacerbations are a major disease burden and predominantly caused by infection with rhinovirus (RV) -the common cold virus- [11–14]. Importantly some asthmatics display impaired innate immune responses with deficient type 1 and 3 interferon (IFN) responses upon RV infection [15,16]. Corticosteroids are the mainstream anti-inflammatory treatment used in asthmatics and have been effective in reducing eosinophilic inflammation. However, their therapeutic efficacy in preventing neutrophilic and RV-induced inflammation and symptoms is thought to be limited . Furthermore, side effects can be observed in asthmatics requiring high dose or systemic corticosteroid treatment. In some patients asthma is steroid-resistant and then difficult to control [18,19]. Thus novel therapeutic strategies for severe asthma and RV-induced exacerbations are required.
Mitoxantrone belongs to the clinically useful topoisomerase 2-targeting anthraquinones that is used to treat metastatic breast cancer, leukemia, and lymphoma [20–22]. Mitoxantrone disrupts DNA synthesis and repair causing single and double-strand breaks by intercalating the DNA through hydrogen binding  resulting in non-specific cytotoxicity [20–22]. In patients with relapsing multiple sclerosis mitoxantrone may be of therapeutic benefit as a potent immunosuppressive agent targeting proliferating macrophages, B and T lymphocytes [24,25]. Recently topoisomerase 2-independent effects of mitoxantrone have also been described that may be of relevance for therapeutically modulating the aberrant immune response observed in asthma and RV-induced exacerbations. Specifically, mitoxantrone inhibited hypoxia-inducible factor (HIF)-1α and vascular endothelial growth factor (VEGF) expression through dephosphorylation of AKT in transformed cell lines suggesting that mitoxantrone regulates the phosphoinositide-3-kinase (PI3K)/AKT pathway .
Importantly several lines of evidence suggest that inhibition of the PI3K effector pathway may be a potential therapeutic strategy for asthma and RV-induced exacerbations [27–29]. Recently it has been shown that the TH2 cytokine IL-25 promotes angiogenesis, at least in part, by increasing VEGF/VEGF receptor expression through PI3K/and Erk/MAPK pathways . Osteopontin is upregulated by epithelial cells and macrophages in the lungs of asthmatics that in turn activates PI3K/AKT downstream signaling pathways to induce IL-13, AHR, mucus hypersecretion, and pro-matrix metalloproteinase-9 in the lungs . Receptor-mediated mast cell growth, differentiation, homing to their target tissues, survival and activation are also controlled, to varying degrees, by PI3K-driven pathways . Finally, PI3K/AKT signaling is required for maximal RV-induced neutrophilic airway inflammation in an experimental mouse model and RV-induced IL-8 expression by airway epithelial cells, likely via its essential role in virus internalization [33,34].
In this study, the effects of mitoxantrone and a novel non-cytotoxic anthraquinone derivative (O,O´-didodecanoyl-1,4-dihydroxyanthraquinone) on allergic airways disease (AAD) and RV-induced exacerbation was investigated. We show that anthraquinone treatment reduced AKT phosphorylation, HIF-α and VEGF expression, and ameliorated allergen- and RV-induced airways hyprereactivity, neutrophilic and eosinophilic inflammation, cytokine/chemokine expression, mucus hypersecretion, and expression of TH2 factors in the airways. Anthraquinones also boosted type 1 interferon (IFN) responses and limited RV replication in the lung.
Male BALB/c mice, 6-8 weeks old, were obtained from the Specific Pathogen Free Facility of the University of Newcastle. The Animal Care and Ethics Committee of the University of Newcastle, Australia approved all experiments.
Preparation of anthraquinone derivatives
1,4-dihydroxyanthraquinone was dissolved in dimethylacetamide and pyridine at 0°C and dodecanoyl chloride added. The reaction mixture was stirred at 0°C to room temperature for 24 hrs. The light yellow precipitate was washed with hexane. Mitoxantrone (Quiral Quimica do Brasil S.A., Juiz de Fora, MG, Brazil) and its analog was solubilized in DMSO (Sigma, USA), never exceeding 0.1% (v/v) and diluted in 0.9% sterile saline.
Induction of AAD and rhinovirus-induced exacerbation
Mice were intranasally sensitized with house dust mite extract (HDM; 50μg daily at day 0, 1 and 2) followed by intranasal challenges (5μg daily from day 14 to day 17) delivered in 50μl of 0.9% sterile saline. Non-sensitized mice received sterile saline only. Mice were euthanized 24hrs after the last allergen challenge.
Four groups of mice were studied: non-allergic (SALINE), HDM allergic and vehicle treated (VEHICLE, DMSO 0.1%), HDM allergic and mitoxantrone treated (MITOXANTRONE 1mg/kg as previously described), HDM allergic and analog treated (ANALOG 1mg/kg) mice. Treatments (100mcl/mouse/day) were administered intraperitoneally from day 12 to day 17 during HDM challenges and after HDM sensitization. In another series of experiments mice were intranasally infected with minor group RV (RV1B) – 50µl containing 1x107 virions – or UV-inactivated RV1B at day 18 which was 24hrs after the last HDM challenge to exacerbate preexisting AAD. Mice were euthanized 24hrs after the RV1B infection.
AHR was invasively assessed in separate groups of anesthetized mice by measurement of total lung resistance in response to increasing doses of methacholine as previously described. Percentage increase over baseline (water) in response to nebulized methacholine was calculated.
Collection of bronchoalveolar lavage fluid
Twenty-four hours after the last HDM challenge, bronchoalveolar lavage (BAL) fluid was performed by cannulating the trachea and instillation of 800 µl of Hank's Buffered Salt Solution (HBSS) three times.
Total and differential cell counts
BAL fluid was centrifuged at 800 x g for 10 min at 4°C and cell-free supernatant was collected. Cells were resuspended in 100µl of HBSS and total number of viable cells was determined by trypan blue exclusion in a Neubauer cell chamber. Cytospins were prepared and slides were stained with May-Grunwald-Giemsa. Differential cell counts were determined from a total of 200 cells per slide.
Quantitative Real time PCR
Lower airway tissue from the left lung of each animal was separated by blunt dissection and stored in RNA later (Ambion, USA) at -80°C. Total RNA was extracted from the airways according to the manufacturer's instructions (mirVana m/miRNA isolation kit, Ambion, USA). The primers used were synthesized by Sigma (Table 1). qRT-PCRs reactions were performed using the SYBR® Green (Kappa Biosystems, USA) according to manufacturer's instructions. After amplification all samples were subjected to dissociation curve analysis in order to validate the absence of nonspecific products and primer dimers. RNA was normalized to expression levels of Hypoxanthine-guanine phosphoribosyl transferase (HPRT) and relative expression was calculated with the 2-ΔΔCt method.
Airway morphology analysis
The right lower lung lobe from each animal was fixed in 10% buffered formalin and the samples were subjected to routine histologic procedures and then stained with periodic acid-Schiff (PAS) to identify mucus glycoconjugates, Toluidine blue to identify mast cells, or Carbol’s chromotrope-hematoxylin to identify eosinophils. Cells were identified by morphological criteria and quantified by counting ten high-powered fields (HPF) in each slide.
Measurement of cytokines
Peribronchial lymph nodes were excised, filtered and cultured in the presence of HDM (50μg/ml) for 6 days. Levels of IL-13, IL-5 and IFN-γ in supernatants were determined by ELISA (BD Biosciences Pharmingen, USA) according to the manufacturer's instructions. CD4+ T-cells were isolated from the draining lymph nodes using an Auto Macs Pro (Miltenyi Biotec, USA) according to the manufacturer’s instructions. Levels of IL-4 and IL-13 were measured concurrently by multiplex using the Novex platform (Invitrogen, USA) according to the manufacturer’s instructions before being quantified using a Bioplex (Biorad, USA) luminex system. Whole mouse lungs were homogenized with a Tissue Tearor (Biospec Products, USA) on ice in lysis buffer.
To prepare single-cell suspensions from whole lung and lymph nodes, tissues were gently mashed through 100µm cell strainers (BD Falcon). Red blood cells were removed using lysis buffer (4.15g ammonium chloride, 1g sodium hydrogen carbonate, 0.0185g EDTA in 500ml of dH2O). Cells were counted and the Fc receptor was blocked. Cell surface expression of CD4 (PE), CD8 (PerCP), TCRβ (FITC), CD3e (APC), CD19 (PerCP), CD11b (PerCP), CD11c (FITC), F4/80 (APC) and MHCII (PE) (all antibodies from Pharmingen, USA) was determined by flow cytometry analysis with a FACSCanto flow cytometer using commercially available Abs from BD Biosciences. Cells gated by forward- and side-scatter parameters were analyzed using FACSDiva software.
p-AKT Western blot
Levels of p-AKT were determined by western blotting in whole cell protein lysates isolated from lung homogenates. Protein samples at 45 μg/lane underwent electrophoresis on a 10% SDS-polyacrylamide gel and were electroblotted onto PVDF. Membranes were blocked for 2h at room temperature in TBS containing 5% bovine serum albumin (Sigma), the membrane was incubated for 2h at room temperature with monoclonal anti p-AKT (1:300 in a TBST solution made up with 10ng/ml of B-Actin). After washing the membrane 3x for 5min in TBST the membrane was incubated with HEP-conjugated secondary antibody (1:5000 in TBST) for 1h at room temperature. The membrane was incubated with Luminata Cresecendo Western HRP Substrate (Millipore) and visualized on a Fujifilm LAS-4000 using Image reader LAS-4000.
Determination of PIP3 activity
Levels of active phosphatidylinositol-(3,4,5)-trisphosphate (PIP3) were determined by ELISA (Echelon Biosciences, USA) according to the manufacturer’s instructions.
Numerical data were analyzed for normal distribution employing the Kolmogorov-Smirnov test. Subsequently, the unpaired t test was used for parametric data or Mann Whitney test for nonparametric data. The significance level accepted for the tests was p<0.05. Data are expressed as mean ± standard error of the mean (SEM).
Treatment with anthraquinones ameliorates hallmark features of AAD
The ability of mitoxantrone to intercalate with the DNA through hydrogen binding was precluded by synthesizing a novel anthraquinone derivative, O,O´-didodecanoyl-1,4-dihydroxyanthraquinone (Figure 1A). Consequently, this analog did not exhibit any in-vitro cytotoxicity on transformed macrophage cell lines or cytotoxic effects in-vivo (data not shown). In order to investigate the anti-inflammatory properties of mitoxantrone and its analog on AAD, we sensitized and challenged BALB/c mice with HDM via the airway route which resulted in the development of AHR (Figure 1B) and increased cellularity in BAL fluid (Figure 1C) consisting of eosinophils, lymphocytes, and neutrophils (Figure 1D). Treatment with mitoxantrone or its non-cytotoxic analog significantly reduced AHR and airways inflammation (Figure 1C and D). To further investigate the effect of mitoxantrone and its analog on accumulation of lymphocyte subsets in the lungs and peribronchial lymph nodes (PBLN) FACS analysis was performed. Both mitoxantrone and its analog impaired recruitment of T cells (CD3+), CD4+ and CD8+ T helper cells, and CD19+ B cells into the lungs (Figure 1E) while those cells accumulated in the PBLN (Figure 1F). Mucus hypersecretion, Muc5ac expression, and mast cell influx were also significantly reduced upon mitoxantrone or analog treatment (Figure 2 A to K).
(A) Scheme of chemical synthesis of the anthraquinone derivative O,O´-didodecanoyl-1,4-dihydroxyanthraquinone. (B) AHR, (C) total and (D) differential number of BALF cells, (E) T (CD4, CD8) and B (CD19) cell numbers in lung homogenates and (F) peribronchial lymph node cells in HDM sensitized and challenged mice treated with 1 mg/kg of mitoxantrone or analog. * p<0.05 when compared to vehicle. Data represent the mean±SEM of at least two independent experiments n=6.
Fixed airway sections stained with (A-D) Periodic acid-Schiff (PAS) staining or Toluidine blue (G-J) from non-allergic saline treated mice (A, E), vehicle (B, F), mitoxantrone (C, G) and analog (D, H) treated allergic mice; bar 50 μm. (I) Mucus cells counted in ten high-powered fields (100 µm2) of the PAS stained lungs; (J) RT-PCR with RNA isolated from lower airway tissue; data normalized to HPRT and the relative expression of Muc5ac calculated relative to saline; (K) Mast cell counts in ten high-powered fields (100 µm2) of the Toluidine blue stained lungs; * p<0.05 when compared to vehicle. Data represent the mean±SEM of at least two independent experiments n=6.
Anthraquinones impair expression of pro-inflammatory cytokines along with regulatory transcriptional factors in the lung
IL-13 and IL-5 release from in-vitro HDM-stimulated PBLN cells was significantly impaired in allergic mice treated with the antraquinone analog while IFN-γ release was increased (Figure 3 A to C). HDM-stimulated CD4+ T cells isolated from mice treated with the antraquinone analog released lower levels of the archetypal TH2 cytokines IL-4 and IL-13 (Figure 3 D to E). Expression of cytokines promoting TH17 immunity such as IL-17F, IL-17A, IL-6, and IL-23p19 were also reduced (Figure 3 F to I) but we were not able to detect IL-17 protein in CD4+ T cell or PBLN supernatants, or lung homogenates. Other pro-inflammatory factors such as TNF-α, CCL8 and CXCL10 were also reduced in analog treated allergic mice (Figure 3J and K). Same results were observed with mitoxantrone-treated mice (data not shown). The reduction in TH2 and T17 cytokine expression upon analog treatment was associated with impaired expression of STAT6, STAT3, and ROR-γT (Figure 4A to C).
(A) IL-13, (B) IL-5, and (C) IFN-λ release from peribronchial lymph node cells cultured in the presence of HDM (50µg/ml). (D) IL-4 and (E) IL-13 release form CD4+ T-cells cultured in the presence of HDM (50µg/ml). RT-PCRs with RNA isolated from lower airway tissue; data normalized to HPRT and the relative expression of (F) IL-17A, (G) IL-17F, (H) IL-6, (I) IL-23p19, (J) TNF-α, (K) CCL8 and (L) CXCL10 was calculated relative to saline. * p<0.05 when compared to vehicle. Data represent the mean±SEM of at least two independent experiments n=6.
BALB/c mice were sensitized and challenged with HDM intranasally and treated with 1 mg/kg of analog. RT-PCRs with RNA isolated from lower airway tissue; data normalized to HPRT and the relative expression of (A) STAT6, (B) STAT3, (C) ROR-γT and (D) FOXP3 was calculated relative to expression in saline. * p<0.05 when compared to vehicle. Data represent the mean±SEM of at least two different experiments n=6.
p-AKT phosphorylation, HIF-1α and VEGF expression are limited by anthraquinone treatment
In accordance with in vitro observations  anthraquinone treatment of allergic mice reduced HIF-1α and VEGF expression along with reduced levels of p-AKT and active PIP3 in the lungs (Figure 5A to D).
(A) Protein lung lysates were isolated from allergic mice and levels of p-AKT1/2/3 were determined by western blotting. Signal strength of p-AKT when compared to total actin level. (B) PIP3 activity in lung lysates. (C-D) RT-PCRs with RNA isolated from lower airway tissue; data normalized to HPRT and the relative expression of (C) HIF-1α and (D) VEGF was calculated to saline expression levels. * p<0.05 when compared to vehicle. Data represent the mean±SEM of at least two independent experiments n=6.
RV-induced exacerbation of AAD and RV replication are reduced by anthraquinone treatment
AHR is further exacerbated by RV1B infection of allergic mice as compared to mice exposed to UV-inactivated RV1B (Figure 6A). Notably, treatment with one dose of analog 24hrs before RV exposure resulted in marked attenuation of AHR to levels that are comparable to allergic mice exposed to UV-inactivated RV1B (Figure 6A). This was associated with inhibition of RV-induced exacerbation of eosinophilic and neutrophilic airways inflammation (Figure 6B). Interestingly anthraquinone treatment also impaired RV1B replication (Figure 6C) and increased expression of innate antiviral type 1 IFNs (Figure 6D and E).
24hrs after the last HDM challenge, allergic mice were infected with 50µl of RV1B (RV) or UV-inactivated RV1B (UVRV). (A) 24hrs after RV1B infection AHR was determined. (B) Differential number of cells in the BALF. RT-PCRs with RNA isolated from lower airway tissue; data normalized to HPRT, (C) the absolute copy numbers of RV, and the relative expression of (D) IFN-α and (E) IFN-β was calculated relative UVRV expression levels. * p<0.05 when compared to vehicle+RV. Data represent the mean±SEM of at least two independent experiments n=6.
In the present work, treatment with O,O´-didodecanoyl-1,4-dihydroxyanthraquinone, a new non-cytotoxic anthraquinone derivative and analog of mitoxantrone, reduced the characteristic hallmark features of AAD including AHR, airways inflammation with eosinophils, neutrophils and mast cells, T-cell recruitment into the lung, expression of TH2 and TH17 transcriptional factors, release of TH2 cytokines, mucus hypersecretion, and RV-induced exacerbation. Moreover, anthraquinone treatment boosted antiviral IFN responses and limited RV replication.
There is a need for improved therapies for patient with severe asthma as it accounts for 5% to 10% of cases and causes 50% of total asthma-related health costs . For instance, humanized antibodies that ameliorate TH2 effector pathways by blocking circulating IgE (omalizumab) or IL-5 (mepolizumab) reduced exacerbations and need for other medication and improved asthma control [37–41]. Anti-IL-13 treatment (lebrikizumab) was associated with improved lung functions .
Severe asthma is also associated with increased IL-17A production  and studies in experimental models suggest a critical role for complement-mediated regulation of the IL-23-TH17 axis by enhancing IL-13-driven responses . IL-17-expressing cells may promote neutrophilic inflammation, which is related to low lung function, worse asthma control, and increased exacerbations [43,45,46]. Children with severe asthma also displayed reduced levels of IFN-γ in their BALF, which –among other markers- best characterized severe versus moderate asthma . Thus, severe asthma is not simply a TH2-mediated disease but may involve aberrant activation of TH17 cells  and accumulation of neutrophils in the airways . Notably, our experimental studies could suggest that anthraquinones affects the IL-23-TH17 axis because we found reduced expression of IL-17F, IL-17A, IL-6, and IL-23p19. However, we could not detect IL-17 protein in lung samples or PBLN or CD4+ cell supernatant precluding us to conclusively investigate the effect of anthraquinonones on this pathway.
RV-induced exacerbation of asthma is common and responds only partially to steroid treatment resulting in hospitalizations and contributing to asthma mortality. We have observed in our experimental HDM-mediated AAD model of RV-induced exacerbation that the development of AHR is only partially inhibited by systemic dexamethasone treatment and neutrophilic inflammation remains unaffected while RV-induced eosinophil influx is greatly reduced (data not shown). We show here that steroid-resistant, RV-induced AHR and neutrophilic inflammation are abolished by treatment with one dose of mitoxantrone analog before RV exposure. This effect may be explained by a boost in IFN production with subsequent inhibition of RV replication (Figure 6) as a consequence of therapeutically modulating TH cell effector pathways. This conclusion is supported by studies in asthmatics that showed an inverse relationship between RV replication and IFN production . Alternatively the deficiency in IFN production upon RV infection -which is observed in some asthmatics [15,16]- may promote aberrant T helper cell activation .
Kinases such as p38 mitogen-activated protein kinase, Jun kinases and PI3K play a key role in regulating inflammatory gene expression in asthmatics . PI3K activation also results in reduced steroid sensitivity through phosphorylation of AKT and subsequent reduced histone deacetylase 2 activity . PI3K inhibitors against isoforms attenuate antigen-induced airway inflammation in murine models [29,54] and might reverse steroid resistance in severe asthmatics . Unselective PI3K inhibitors however are likely to be toxic .
Mitoxantrone has recently been shown to block PI3K signaling through dephosphorylation of AKT in-vitro resulting in reduced HIF-1α and VEGF expression . We have shown here that a non-cytotoxic anthraquinone derivative attenuates the PI3K signaling pathway in-vivo despite its inability to disrupt DNA synthesis and repair due to removal of the hydrogen molecules during chemical synthesis (Figure 1A). Interestingly, Dang et al have recently demonstrated that HIF-1α plays an important role in the alternate induction of TH17 cells . Furthermore inhibition of HIF-1α attenuated OVA-induced AHR and inflammation via VEGF suppression in bronchial epithelium , which is a critical effector molecule in Th2 driven allergic disease in the lung [58,59].
Recently Emodin and Citreorosein, two naturally occurring anthraquinone derivatives, have been shown to suppress IgE-mediated anaphylactic reaction, mast cell activation, and leukotriene generation [60,61]. This was associated with blockage of antigen-triggered phosphorylation of Syk, a receptor-proximal tyrosine kinase targeted by anthraquinones, which regulates the PI3K pathway through the adaptor protein NTAL  and plays a key role in NF-κB-mediated expression of COX-2 and pro-inflammatory cytokines.
Interestingly, Syk is also phosphorylated upon RV binding to its cell surface receptor and regulates clathrin-mediated RV endocytosis through the activation of the PI3K/AKT signaling pathway . Our results highlight the in-vivo relevance of this pathway by demonstrating limited RV replication, AHR and airways inflammation in allergic mice treated with anthraquinone derivatives.
The PI3K/AKT signaling pathway is also activated by HDM allergen Der p1 binding to protease-activated receptors  and LPS (e.g. in crude HDM extract) sensing by TLR4 . Thus employing non-cytotoxic anthraquinone derivatives may be of therapeutic benefit for the treatment of both allergen- and RV-triggered severe asthma (Figure 7).
We appreciate the technical assistance from Ana Pereira de Siqueira, Jason Girkin, Leon Sokulsky, Jane Grehan, and the staff from the Animal Care Facility of the contributing institutes.
Conceived and designed the experiments: JM APF MVA CFC CCSA PSF. Performed the experiments: CCSA AC LH MP MM. Analyzed the data: CCSA AC LH MP JM. Contributed reagents/materials/analysis tools: JM SLJ APF MVA CFC. Wrote the manuscript: CCSA AC JM HCT PSF APF MVA CFC.
- 1. Dunn JJ, Woolstenhulme RD, Langer J, Carroll KC (2004) Sensitivity of respiratory virus culture when screening with R-mix fresh cells. J Clin Microbiol 42: 79-82. doi:10.1128/JCM.42.1.79-82.2004. PubMed: 14715735.
- 2. Bochner BS, Undem BJ, Lichtenstein LM (1994) Immunological aspects of allergic asthma. Annu Rev Immunol 12: 295-335. doi:10.1146/annurev.iy.12.040194.001455. PubMed: 8011284.
- 3. Kay AB (2005) The role of eosinophils in the pathogenesis of asthma. Trends Mol Med 11: 148-152. doi:10.1016/j.molmed.2005.02.002. PubMed: 15823751.
- 4. Broide DH (2008) Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 121: 560-570. doi:10.1016/j.jaci.2008.01.031. PubMed: 18328887.
- 5. Lloyd C (2002) Chemokines in allergic lung inflammation. Immunology 105: 144-154. doi:10.1046/j.1365-2567.2002.01344.x. PubMed: 11872089.
- 6. Holgate ST, Roberts G, Arshad HS, Howarth PH, Davies DE (2009) The role of the airway epithelium and its interaction with environmental factors in asthma pathogenesis. Proc Am Thorac Soc 6: 655-659. doi:10.1513/pats.200907-072DP. PubMed: 20008870.
- 7. Lambrecht BN, Hammad H (2009) Biology of lung dendritic cells at the origin of asthma. Immunity 31: 412-424. doi:10.1016/j.immuni.2009.08.008. PubMed: 19766084.
- 8. Wills-Karp M LJ, Xu X, Schofield B, Neben TY, Karp CL et al. (1998) Interleukin-13: central mediator of allergic asthma. Science 282: 2258-2261. doi:10.1126/science.282.5397.2258. PubMed: 9856949.
- 9. Kuperman DA, Huang X, Koth LL, Chang GH, Dolganov GM et al. (2002) Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat Med, 8: 885–9. PubMed: 12091879.
- 10. Mattes J, Yang M, Siqueira A, Clark K, MacKenzie J et al. (2001) IL-13 induces airways hyperreactivity independently of the IL-4R alpha chain in the allergic lung. J Immunol 167: 1683-1692. PubMed: 11466392.
- 11. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F et al. (1995) Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. Bmj 310: 1225-1229. doi:10.1136/bmj.310.6989.1225. PubMed: 7767192.
- 12. Friedlander SL, Busse WW (2005) The role of rhinovirus in asthma exacerbations. Clin Infect Dis 116: 267-273. PubMed: 16083778.
- 13. Sears MR (2008) Epidemiology of asthma exacerbations. J Allergy Clin Immunol 122: 662-670; quiz: 19014756.
- 14. Miller EK (2010) New human rhinovirus species and their significance in asthma exacerbation and airway remodeling. Immunol Allergy Clin North Am 30: 541-552, vii doi:10.1016/j.iac.2010.08.007. PubMed: 21029937.
- 15. Wark PA, Johnston SL, Bucchieri F, Powell R, Puddicombe S et al. (2005) Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J Exp Med 201: 937-947. doi:10.1084/jem.20041901. PubMed: 15781584.
- 16. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA et al. (2006) Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12: 1023-1026. doi:10.1038/nm1462. PubMed: 16906156.
- 17. Grünberg K, Sharon RF, Sont JK; In 't Veen JC, Van Schadewijk WA, et al. (2001) Rhinovirus-induced airway inflammation in asthma: effect of treatment with inhaled corticosteroids before and during experimental infection. Am J Respir Crit Care Med 164: 1816-1822. doi:10.1164/ajrccm.164.10.2102118. PubMed: 11734429. PubMed: 11734429.
- 18. Leung DY, Szefler SJ (1998) New insights into steroid resistant asthma. Pediatr Allergy Immunol Off Publ European Society Of Pediatric Allergy And Immunology 9: 3-12. doi:10.1111/j.1399-3038.1998.tb00293.x. PubMed: 9560836.
- 19. Leung DY, Szefler SJ (1997) Diagnosis and management of steroid-resistant asthma. Clin Chest Med 18: 611-625. doi:10.1016/S0272-5231(05)70405-6. PubMed: 9329880.
- 20. Alberts DS, Peng YM, Bowden GT, Dalton WS, Mackel C (1985) Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest New Drugs 3: 101-107. PubMed: 4040505.
- 21. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9: 338-350. doi:10.1038/nrc2607. PubMed: 19377506.
- 22. Faulds D, Balfour JA, Chrisp P, Langtry HD (1991) Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs 41: 400-449. doi:10.2165/00003495-199141030-00007. PubMed: 1711446.
- 23. Smith IE (1983) Mitoxantrone (novantrone): a review of experimental and early clinical studies. Cancer Treat Rev 10: 103-115. doi:10.1016/S0305-7372(83)80014-0. PubMed: 6347376.
- 24. Neuhaus O, Kieseier BC, Hartung HP (2004) Mechanisms of mitoxantrone in multiple sclerosis--what is known? J Neurol Sci 223: 25-27. doi:10.1016/j.jns.2004.04.015. PubMed: 15261556.
- 25. Fox EJ (2006) Management of worsening multiple sclerosis with mitoxantrone: a review. Clinical Therapeutics 28: 461-474. doi:10.1016/j.clinthera.2006.04.013. PubMed: 16750460.
- 26. Toh YM, Li TK (2011) Mitoxantrone inhibits HIF-1alpha expression in a topoisomerase II-independent pathway. Clin Cancer Res Off J Am Assoc Cancer Res 17: 5026-5037. doi:10.1158/1078-0432.CCR-11-0235.
- 27. Kwak YG, Song CH, Yi HK, Hwang PH, Kim JS et al. (2003) Involvement of PTEN in airway hyperresponsiveness and inflammation in bronchial asthma. J Clin Invest 111: 1083-1092. doi:10.1172/JCI16440. PubMed: 12671058.
- 28. Lee CT, Risom T, Strauss WM (2006) MicroRNAs in mammalian development. Birth Defects Res C Embryo TODAY 78: 129-139. doi:10.1002/bdrc.20072. PubMed: 16847889.
- 29. Takeda M, Ito W, Tanabe M, Ueki S, Kato H et al. (2009) Allergic airway hyperresponsiveness, inflammation, and remodeling do not develop in phosphoinositide 3-kinase γ–deficient mice. J Allergy Clin Immunol 123: 805-812. doi:10.1016/j.jaci.2008.11.047. PubMed: 19232703.
- 30. Corrigan CJ, Wang W, Meng Q, Fang C, Wu H et al. (2011) T-helper cell type 2 (Th2) memory T cell-potentiating cytokine IL-25 has the potential to promote angiogenesis in asthma. Proc Natl Acad Sci U S A 108: 1579-1584. doi:10.1073/pnas.1014241108. PubMed: 21205894.
- 31. Simoes DC, Xanthou G, Petrochilou K, Panoutsakopoulou V, Roussos C et al. (2009) Osteopontin deficiency protects against airway remodeling and hyperresponsiveness in chronic asthma. Am J Respir Crit Care Med 179: 894-902. doi:10.1164/rccm.200807-1081OC. PubMed: 19234104.
- 32. Kim JH, Choi C, Benveniste EN, Kwon D (2008) TRAIL induces MMP-9 expression via ERK activation in human astrocytoma cells. Biochem Biophys Res Commun 377: 195-199. doi:10.1016/j.bbrc.2008.09.095. PubMed: 18834856.
- 33. Newcomb DC, Sajjan US, Nagarkar DR, Wang Q, Nanua S et al. (2008) Human rhinovirus 1B exposure induces phosphatidylinositol 3-kinase-dependent airway inflammation in mice. Am J Respir Crit Care Med 177: 1111-1121. doi:10.1164/rccm.200708-1243OC. PubMed: 18276942.
- 34. Newcomb DC, Sajjan U, Nanua S, Jia Y, Goldsmith AM et al. (2005) Phosphatidylinositol 3-kinase is required for rhinovirus-induced airway epithelial cell interleukin-8 expression. J Biol Chem 280: 36952-36961. doi:10.1074/jbc.M502449200. PubMed: 16120607.
- 35. Thomson NC, Chaudhuri R, Spears M (2011) Emerging therapies for severe asthma. BMC Med 9: 102. doi:10.1186/1741-7015-9-102. PubMed: 21896202.
- 36. Weckmann M, Collison A, Simpson JL, Kopp MV, Wark PAB et al. (2007) Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med 13: 1308-1315. doi:10.1038/nm1660. PubMed: 17934471.
- 37. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A et al. (2001) Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108: 184-190. doi:10.1067/mai.2001.117880. PubMed: 11496232.
- 38. Busse WW, Morgan WJ, Gergen PJ, Mitchell HE, Gern JE et al. (2011) Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 364: 1005-1015. doi:10.1056/NEJMoa1009705. PubMed: 21410369.
- 39. Lanier B, Bridges T, Kulus M, Taylor AF, Berhane I et al. (2009) Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 124: 1210-1216. doi:10.1016/j.jaci.2009.09.021. PubMed: 19910033.
- 40. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W (2009) Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360: 973-984. doi:10.1056/NEJMoa0808991. PubMed: 19264686.
- 41. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A et al. (2009) Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 360: 985-993. doi:10.1056/NEJMoa0805435. PubMed: 19264687.
- 42. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV et al. (2011) Lebrikizumab Treatment in Adults with Asthma. N Engl J Med 3: 3. PubMed: 21812663.
- 43. Al-Ramli W, Prefontaine D, Chouiali F, Martin JG, Olivenstein R et al. (2009) TH17-associated cytokines (IL-17A and IL-17F)in severe asthma. J Allergy Clin Immunol 123.
- 44. Lajoie S, Lewkowich IP, Suzuki Y, Clark JR, Sproles AA et al. (2010) Complement-mediated regulation of the IL-17A axis is a central genetic determinant of the severity of experimental allergic asthma. Nat Immunol 11: 928-935. doi:10.1038/ni.1926. PubMed: 20802484.
- 45. Simpson JL, Scott R, Boyle MJ, Gibson PG (2006) Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 11: 54-61. doi:10.1111/j.1440-1843.2006.00784.x. PubMed: 16423202.
- 46. Hastie AT, Moore WC, Meyers DA, Vestal PL, Li H et al. (2010) Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 125: 1028-1036 e1013 doi:10.1016/j.jaci.2010.02.008. PubMed: 20398920.
- 47. Fitzpatrick AM, Higgins M, Holguin F, Brown LA, Teague WG (2010) The molecular phenotype of severe asthma in children. J Allergy Clin Immunol 125: 851-857 e818 doi:10.1016/j.jaci.2010.01.048. PubMed: 20371397.
- 48. Wang Q, Miller DJ, Bowman ER, Nagarkar DR, Schneider D et al. (2011) MDA5 and TLR3 initiate pro-inflammatory signaling pathways leading to rhinovirus-induced airways inflammation and hyperresponsiveness. PLOS Pathog 7: e1002070. PubMed: 21637773.
- 49. Wenzel SE, Szefler SJ, Leung DY, Sloan SI, Rex MD et al. (1997) Bronchoscopic evaluation of severe asthma. Persistent inflammation associated with high dose glucocorticoids. Am J Respir Crit Care Med 156: 737-743. doi:10.1164/ajrccm.156.3.9610046. PubMed: 9309987.
- 50. Message SD, Laza-Stanca V, Mallia P, Parker HL, Zhu J et al. (2008) Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proc Natl Acad Sci U S A 105: 13562-13567. doi:10.1073/pnas.0804181105. PubMed: 18768794.
- 51. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL (2002) A defective type 1 response to rhinovirus in atopic asthma. Thorax 57: 328-332. doi:10.1136/thorax.57.4.328. PubMed: 11923551.
- 52. Barnes PJ (2012) Severe asthma: advances in current management and future therapy. J Allergy Clin Immunol 129: 48-59. doi:10.1016/j.jaci.2011.11.006. PubMed: 22196524.
- 53. To Y, Ito K, Kizawa Y, Failla M, Ito M et al. (2010) Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182: 897-904. doi:10.1164/rccm.200906-0937OC. PubMed: 20224070.
- 54. Lee KS, Park SJ, Kim SR, Min KH, Jin SM et al. (2006) Phosphoinositide 3-kinase-δ inhibitor reduces vascular permeability in a murine model of asthma. J Allergy Clin Immunol 118: 403-409. doi:10.1016/j.jaci.2006.04.041. PubMed: 16890765.
- 55. Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7: 191-201. doi:10.1038/nri2036. PubMed: 17290298.
- 56. Dang Eric V, Barbi J, Yang H-Y, Jinasena D, Yu H et al. (2011) Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1. Cell 146: 772-784. doi:10.1016/j.cell.2011.07.033. PubMed: 21871655.
- 57. Kim SR, Lee KS, Park HS, Park SJ, Min KH et al. (2010) HIF-1α inhibition ameliorates an allergic airway disease via VEGF suppression in bronchial epithelium. Eur J Immunol 40: 2858-2869. doi:10.1002/eji.200939948. PubMed: 20827786.
- 58. Lee CG, Ma B, Takyar S, Ahangari F, DelaCruz C et al. (2011) Studies of Vascular Endothelial Growth Factor in Asthma and Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 8: 512-515. doi:10.1513/pats.201102-018MW. PubMed: 22052929.
- 59. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S et al. (2004) Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 10: 1095-1103. doi:10.1038/nm1105. PubMed: 15378055.
- 60. Lu Y, Yang JH, Li X, Hwangbo K, Hwang SL et al. (2011) Emodin, a naturally occurring anthraquinone derivative, suppresses IgE-mediated anaphylactic reaction and mast cell activation. Biochem Pharmacol 82: 1700-1708. doi:10.1016/j.bcp.2011.08.022. PubMed: 21907188.
- 61. Lu Y, Li Y, Jahng Y, Son JK, Chang HW (2012) Citreorosein inhibits degranulation and leukotriene C(4) generation through suppression of Syk pathway in mast cells. Mol Cell Biochem 365: 333-341. doi:10.1007/s11010-012-1273-3. PubMed: 22395859.
- 62. Kambayashi T, Koretzky GA (2007) Proximal signaling events in Fc epsilon RI-mediated mast cell activation. J Allergy Clin Immunol 119: 544-553; quiz: 17336609.
- 63. Lau C, Wang X, Song L, North M, Wiehler S et al. (2008) Syk associates with clathrin and mediates phosphatidylinositol 3-kinase activation during human rhinovirus internalization. J Immunol 180: 870-880. PubMed: 18178826.
- 64. Shi J, Luo Q, Chen F, Chen D, Xu G et al. (2010) Induction of IL-6 and IL-8 by house dust mite allergen Der p1 in cultured human nasal epithelial cells is associated with PAR/PI3K/NFkappaB signaling. ORL J Otorhinolaryngol Relat Spec 72: 256-265. doi:10.1159/000312687. PubMed: 20733339.
- 65. Bauerfeld CP, Rastogi R, Pirockinaite G, Lee I, Hüttemann M et al. (2012) TLR4-mediated AKT activation is MyD88/TRIF dependent and critical for induction of oxidative phosphorylation and mitochondrial transcription factor A in murine macrophages. J Immunol 188: 2847-2857. doi:10.4049/jimmunol.1102157. PubMed: 22312125.